Drug intelligence / Profile preview

KP172

Development stage: Preclinical
Lead developer: Korea Pharma

Overview

KP172 is an investigational drug candidate currently in the discovery phase, developed by Korea Pharma for the treatment of Alzheimer's dementia. It is part of the company's early-stage research and development pipeline focused on neurodegenerative diseases. As a discovery-stage asset, specific details regarding its chemical structure, modality, and precise molecular target have not been publicly disclosed by the sponsor. The program represents Korea Pharma's commitment to expanding its portfolio in the central nervous system (CNS) therapeutic area.

Beyond the preview

Go deeper on KP172.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KP172.

Explore the full profile